RT Journal Article
SR Electronic
T1 Optimization of Microbiological Laboratory Detection Strategy for Patients in A Designated Hospital Treating Novel Coronavirus Pneumonia in Anhui Province
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.21.20039065
DO 10.1101/2020.03.21.20039065
A1 Chang, Wenjiao
A1 Shi, Yuru
A1 Qi, Yingjie
A1 Liu, Jiaxing
A1 Liu, Ting
A1 Chen, Zhaowu
A1 Zhang, Wenjing
A1 Wang, Mengmeng
A1 Liu, Dongfeng
A1 Yin, Ming
A1 Xu, Jing
A1 Yang, Yun
A1 Zhu, Xiaowu
A1 Ge, Jing
A1 Zhu, Shu
A1 Gao, Yong
A1 Ma, Xiaoling
YR 2020
UL http://medrxiv.org/content/early/2020/03/23/2020.03.21.20039065.abstract
AB Novel coronavirus pneumonia (NCP) is an emerging, highly contagious community acquired pneumonia (CAP) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Highly efficient and accurate microbiological laboratory assay is essential to confirm the SARS-CoV-2 infection, rule out other pathogens that can cause CAP, and monitor secondary infections. Here, we enrolled and provide microbiological analysis for 129 suspected and 52 transferred confirmed NCP patients hospitalized in the First Affiliated Hospital of University of Science and Technology of China (USTC) from Jan 21 to Feb 29, 2020. By analyzing the dual swab samples (sputum and pharyngeal) from 129 suspected patients with realtime RT-PCR, we confirmed 33 SARS-CoV-2 infections, with two co-infection cases with adenovirus or rhinovirus. We also used multiplex PCR to detect 13 common respiratory tract pathogens in 96 non-NCP patients, and found that 30 patients (31.25%) were infected with at least one respiratory tract pathogen that may cause CAP. Further, we performed bacterial and fungal cultures as well as fungal serologic tests and found that there is no secondary bacterial/fungal infections in confirmed NCP patients. Our studies suggest that, during the epidemic of NCP in Anhui province, there was a certain proportion of infection and co-infection of other common pathogens of CAP, and the secondary bacterial and fungal infection is not detectable in NCP patients. In comparison with SARS-CoV-2 detection alone, this optimized strategy combining multiple pathogen detection for identification of NCP and other CAP patients as well as cultures and serologic tests for confirmed patients increases the diagnosis efficiency and facilitates the personalized medication.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by Special Project for Emergency Scientific and Technological Research on New Coronavirus Infection (XM, No. YD9110002001) supported by “the Fundamental Research Funds for the Central Universities”, National Natural Science Foundation of China (grant 81772248) and the Key Research and Development Plan Project of Anhui Science and Technology Department (YG, No. 201904b11020044).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yeshis manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal.